Evaluation of two RT-PCR screening assays for identifying SARS-CoV-2 variants.

COVID-19 Genome sequencing ID triplex RT-PCR SARS-CoV-2 TaqPath Variants of concern (VOC)

Journal

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
ISSN: 1873-5967
Titre abrégé: J Clin Virol
Pays: Netherlands
ID NLM: 9815671

Informations de publication

Date de publication:
10 2021
Historique:
received: 28 06 2021
revised: 20 08 2021
accepted: 25 08 2021
pubmed: 13 9 2021
medline: 23 9 2021
entrez: 12 9 2021
Statut: ppublish

Résumé

The recent emergence of new SARS CoV-2 variants (variants of concern, VOC) that spread rapidly and may lead to immune escape has emphasized the urgent need to monitor and control their spread. We analyzed 2018 SARS-CoV-2 positive specimens collected between February 9 and March 22, 2021 using the Thermofisher® TaqPath™ COVID-19 CE-IVD RT-PCR kit (TaqPath) and the ID solutions® ID™ SARS-CoV-2/UK/SA Variant Triplex RT-PCR (ID triplex) assay to screen for VOCs. The ID triplex assay identified 62.8% of them as VOCs: 61.8% B.1.1.7 and 0.9% B.1.351/P.1. The agreement between the ID triplex results for B.1.1.7 and the TaqPath S gene target failure (SGTF)/ S gene target late detection (SGTL) profile for this variant agreed very well (k = 0.86). A low virus load was the main cause of discrepancies. Sequencing discordant results with both assays indicated that the TaqPath assay detected the B.1.1.7 lineage slightly better. Both assays suggested that the virus loads of B.1.1.7 variants were significantly higher than those of non-B.1.1.7 strains. Only 10/20 B1.351/P.1 strains detected with the ID triplex assay were confirmed by sequencing. We conclude that the SGTF/SGTL profiles identified using the TaqPath assay and ID triplex results are suitable for detecting the B.1.1.7 lineage. The ID triplex assay, which rapidly determines all three current VOCs simultaneously, could be a valuable tool for limiting virus spread by supporting contact-tracing and isolation.

Sections du résumé

BACKGROUND
The recent emergence of new SARS CoV-2 variants (variants of concern, VOC) that spread rapidly and may lead to immune escape has emphasized the urgent need to monitor and control their spread.
METHODS
We analyzed 2018 SARS-CoV-2 positive specimens collected between February 9 and March 22, 2021 using the Thermofisher® TaqPath™ COVID-19 CE-IVD RT-PCR kit (TaqPath) and the ID solutions® ID™ SARS-CoV-2/UK/SA Variant Triplex RT-PCR (ID triplex) assay to screen for VOCs.
RESULTS
The ID triplex assay identified 62.8% of them as VOCs: 61.8% B.1.1.7 and 0.9% B.1.351/P.1. The agreement between the ID triplex results for B.1.1.7 and the TaqPath S gene target failure (SGTF)/ S gene target late detection (SGTL) profile for this variant agreed very well (k = 0.86). A low virus load was the main cause of discrepancies. Sequencing discordant results with both assays indicated that the TaqPath assay detected the B.1.1.7 lineage slightly better. Both assays suggested that the virus loads of B.1.1.7 variants were significantly higher than those of non-B.1.1.7 strains. Only 10/20 B1.351/P.1 strains detected with the ID triplex assay were confirmed by sequencing.
CONCLUSIONS
We conclude that the SGTF/SGTL profiles identified using the TaqPath assay and ID triplex results are suitable for detecting the B.1.1.7 lineage. The ID triplex assay, which rapidly determines all three current VOCs simultaneously, could be a valuable tool for limiting virus spread by supporting contact-tracing and isolation.

Identifiants

pubmed: 34509927
pii: S1386-6532(21)00236-5
doi: 10.1016/j.jcv.2021.104969
pmc: PMC8411575
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104969

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Auteurs

M Migueres (M)

CHU Toulouse, Hôpital Purpan, Virology Laboratory, 31300, France; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291 - CNRS UMR5051, Toulouse 31300, France; Université Toulouse III Paul-Sabatier, Toulouse, France. Electronic address: migueres.m@chu-toulouse.fr.

S Lhomme (S)

CHU Toulouse, Hôpital Purpan, Virology Laboratory, 31300, France; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291 - CNRS UMR5051, Toulouse 31300, France; Université Toulouse III Paul-Sabatier, Toulouse, France.

P Trémeaux (P)

CHU Toulouse, Hôpital Purpan, Virology Laboratory, 31300, France.

C Dimeglio (C)

CHU Toulouse, Hôpital Purpan, Virology Laboratory, 31300, France.

N Ranger (N)

CHU Toulouse, Hôpital Purpan, Virology Laboratory, 31300, France.

J Latour (J)

CHU Toulouse, Hôpital Purpan, Virology Laboratory, 31300, France.

M Dubois (M)

CHU Toulouse, Hôpital Purpan, Virology Laboratory, 31300, France.

F Nicot (F)

CHU Toulouse, Hôpital Purpan, Virology Laboratory, 31300, France.

M Miedouge (M)

CHU Toulouse, Hôpital Purpan, Virology Laboratory, 31300, France.

J M Mansuy (JM)

CHU Toulouse, Hôpital Purpan, Virology Laboratory, 31300, France.

J Izopet (J)

CHU Toulouse, Hôpital Purpan, Virology Laboratory, 31300, France; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291 - CNRS UMR5051, Toulouse 31300, France; Université Toulouse III Paul-Sabatier, Toulouse, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH